These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 21146128)

  • 1. Membranous nephropathy and malignancy.
    Beck LH
    Semin Nephrol; 2010 Nov; 30(6):635-44. PubMed ID: 21146128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice?
    Hofstra JM; Wetzels JF
    Neth J Med; 2012 Apr; 70(3):109-13. PubMed ID: 22516574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances and prognosis in idiopathic membranous nephropathy.
    Segal PE; Choi MJ
    Adv Chronic Kidney Dis; 2012 Mar; 19(2):114-9. PubMed ID: 22449349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathogenesis of membranous nephropathy: evolution and revolution.
    Glassock RJ
    Curr Opin Nephrol Hypertens; 2012 May; 21(3):235-42. PubMed ID: 22388552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.
    Ronco P; Debiec H
    J Am Soc Nephrol; 2010 Apr; 21(4):564-9. PubMed ID: 20185638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.
    Debiec H; Ronco P
    N Engl J Med; 2011 Feb; 364(7):689-90. PubMed ID: 21323563
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of autoantibodies in primary membranous nephropathy and their clinical significance.
    Stahl RA; Reinhard L; Hoxha E
    Expert Rev Clin Immunol; 2019 Feb; 15(2):165-175. PubMed ID: 30433832
    [No Abstract]   [Full Text] [Related]  

  • 9. Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.
    Pozdzik A; Brochériou I; David C; Touzani F; Goujon JM; Wissing KM
    Biomed Res Int; 2018; 2018():6281054. PubMed ID: 29511687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-Specific IgG Subclasses in Primary and Malignancy-Associated Membranous Nephropathy.
    von Haxthausen F; Reinhard L; Pinnschmidt HO; Rink M; Soave A; Hoxha E; Stahl RAK
    Front Immunol; 2018; 9():3035. PubMed ID: 30619370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in membranous nephropathy: success stories of a long journey.
    Ronco P; Debiec H
    Clin Exp Pharmacol Physiol; 2011 Jul; 38(7):460-6. PubMed ID: 21388432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of membranous nephropathy: a new paradigm in evolution.
    Glassock RJ
    Contrib Nephrol; 2013; 181():131-42. PubMed ID: 23689575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-NEP and anti-PLA2R antibodies in membranous nephropathy: an update].
    Pozdzik AA; Debiec H; I Brochériou ; Husson C; Rorive S; Broeders N; Le Moine A; Ronco P; Nortier J
    Rev Med Brux; 2015; 36(3):166-71. PubMed ID: 26372979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
    Beck LH; Bonegio RG; Lambeau G; Beck DM; Powell DW; Cummins TD; Klein JB; Salant DJ
    N Engl J Med; 2009 Jul; 361(1):11-21. PubMed ID: 19571279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy.
    Svobodova B; Honsova E; Ronco P; Tesar V; Debiec H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1839-44. PubMed ID: 23223223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy.
    Timmermans SA; Ayalon R; van Paassen P; Beck LH; van Rie H; Wirtz JJ; Verseput GH; Frenken LA; Salant DJ; Cohen Tervaert JW;
    Am J Kidney Dis; 2013 Dec; 62(6):1223-5. PubMed ID: 24021909
    [No Abstract]   [Full Text] [Related]  

  • 17. Cellular and molecular biology of membranous nephropathy.
    Couser WG; Nangaku M
    J Nephrol; 2006; 19(6):699-705. PubMed ID: 17173240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is primary membranous nephropathy a complement mediated disease?
    Reinhard L; Stahl RAK; Hoxha E
    Mol Immunol; 2020 Dec; 128():195-204. PubMed ID: 33142137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membranous glomerulopathy: the evolving story.
    Ronco P; Debiec H
    Curr Opin Nephrol Hypertens; 2010 May; 19(3):254-9. PubMed ID: 20110811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.
    Zhang P; Huang W; Zheng Q; Tang J; Dong Z; Jiang Y; Liu Y; Liu W
    J Immunol Res; 2021; 2021():8163298. PubMed ID: 34337081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.